新诺威控股子公司SYS6036注射液获得药物临床试验批准

Core Viewpoint - XinNuoWei (300765) announced that its subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of SYS6036 injection, a humanized monoclonal antibody drug for tumor immunotherapy [1] Group 1 - SYS6036 injection is classified as a Class 3.3 therapeutic biological product [1] - The drug is expected to be used for the treatment of multiple cancers, including melanoma, non-small cell lung cancer, esophageal cancer, and head and neck squamous cell carcinoma [1]